Citation Impact
Citing Papers
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
2010 Standout
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
2012
Ten things you should know about protein kinases: IUPHAR R eview 14
2015
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
2008 Standout
Topological control of cytokine receptor signaling induces differential effects in hematopoiesis
2019 StandoutScienceNobel
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Novel Role of Thromboxane Receptors β Isoform in Bladder Cancer Pathogenesis
2008
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
1989 Standout
Gastric cancer
2016 Standout
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
2006
Second-Line Chemotherapy for Prostate Cancer: Patient Characteristics and Survival
2005
Southwestern Internal Medicine Conference: Clinical Use of Hematopoietic Growth Factors
1993
Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
1993
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
2014 Standout
Colony-stimulating factor-producing tumours: Production of granulocyte colony-stimulating factor and interleukin-6 is secondary to interleukin-1 production
1994 StandoutNobel
Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis
2011
Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited
2009
The resurgence of platinum-based cancer chemotherapy
2007 Standout
First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
2007
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
2012
Gemcitabine in transitional cell carcinoma of the urothelium
2003
Molecular mechanisms of cisplatin resistance
2011 Standout
Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin
1987
Hematopoietic growth factors in cancer patients with invasive fungal infections
1997
Therapeutic potential of β-arrestin- and G protein-biased agonists
2010 StandoutNobel
Targeting cancer with small molecule kinase inhibitors
2008 Standout
Chemotherapy and the war on cancer
2005 Standout
Oesophageal carcinoma
2013 Standout
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
1991 Standout
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Carboplatin: current status and future prospects
1988
Role of granulocyte colony‐stimulating factor as adjunct therapy for septicemia in children with acute leukemia
1995
Generation or large numbers of immature and mature dendritic cells from rat bone marrow cultures
1998 StandoutNobel
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Satraplatin: leading the new generation of oral platinum agents
2009
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
The colony-stimulating factors and cancer
2010
Neutrophils in cancer: neutral no more
2016 Standout
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
The Clinical use of Colony Stimulating Factors
1991
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
2014 StandoutNobel
Satraplatin: an orally available platinum analog for the treatment of cancer
2006
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium
1990
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
2013
VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells
1999 Standout
Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor
1992
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Cancer of the Ovary
2004 Standout
Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy
1992
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Tissue Engineering
1993 StandoutScience
Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor
1990 Standout
Analysis of G-CSF-producing lung cancer cell lines and non-growth-stimulatory effects of rhG-CSF on lung cancer cells in vitro and in vivo
1992
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
2020 Standout
Apoptosis in the Pathogenesis and Treatment of Disease
1995 StandoutScience
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue
2008
Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
2009
The development of anticancer ruthenium(ii ) complexes: from single molecule compounds to nanomaterials
2017 Standout
Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer
2006
Metastatic Urothelial Cancer: Evaluation of Prognostic Factors and Change in Prognosis during the Last Twenty Years
2001
2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
2002 Standout
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
2009 Standout
Radical Cystectomy for Bladder Cancer Today—A Homogeneous Series Without Neoadjuvant Therapy
2003 Standout
Hematopoietic cytokines
2008
Aspergillus fumigatusand Aspergillosis
1999 Standout
Growth Factors and Cancer
1991 StandoutScience
The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis [see comments]
1993
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor–, granulocyte-macrophage colony-stimulating factor–, and interleukin-3–expressing NOD-SCID IL2Rγnull humanized mice
2011 StandoutNobel
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
2008 Standout
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
2005 Standout
Targeted therapy for advanced renal cell carcinoma
2008
The Dendritic Cell Lineage: Ontogeny and Function of Dendritic Cells and Their Subsets in the Steady State and the Inflamed Setting
2013 Standout
Works of C. Sternberg being referenced
Current perspectives in muscle invasive bladder cancer
2002
Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium.
1988
Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer
2008
Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy
1996
Recombinant tumor necrosis factor for superficial bladder tumors
1992
Chemotherapy and management of bladder tumours
2000
Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): Overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial
2008
Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial
2007
An open label, phase II, multicenter, study to evaluate the efficacy and safety of pertuzumab (P) in chemotherapy naïve patients (pts) with hormone refractory prostate cancer (HRPC)
2005
Satraplatin: A new treatment option for patients with hormone refractory prostate cancer
2005
A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC)
2009
Carboplatin: a new platinum analog in the treatment of epidermoid carcinoma of the esophagus.
1985
Circulating baseline plasma cytokines and angiogenic factors (CAF) as markers of tumor burden and therapeutic response in a phase III study of pazopanib for metastatic renal cell carcinoma (mRCC).
2011
Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study.
2011